Company Overview
China Pharma Holdings, Inc. operates within the healthcare sector as a specialized manufacturer of pharmaceutical products for human use within the People's Republic of China. The company focuses on developing, manufacturing, and marketing specific formulations including dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. With a market capitalization of $3.21M, an annual revenue of $4.05M, and an employee count of 224, the organization maintains a relatively small operational footprint typical of specialty niche players. These valuation and revenue figures indicate that the company functions as a micro-cap entity with limited market penetration, suggesting its financial stability is highly sensitive to fluctuations in domestic demand and regulatory changes affecting the generic drug market. The scale of operations, characterized by a modest revenue base and minimal workforce, reflects a business model that relies on product specialization rather than broad market distribution to generate income.
Financial Health
The company reported a revenue of $4.05M over the trailing twelve months, yet it generated a net income of $-3,189,853, while EBITDA stood at $-1,629,531. The substantial gap between positive revenue and negative net income reveals a cost structure where expenses, likely including research, development, or administrative overheads, significantly outpace gross sales, resulting in a loss that is more than double the EBITDA figure. Despite the accounting losses, the firm reported a positive free cash flow of $1.02M, which provides a degree of financial flexibility to fund operations or manage liquidity without immediate reliance on external financing. However, the balance sheet presents significant leverage challenges, as the company holds only $267,625 in cash against total debt of $3.57M, resulting in a debt-to-equity ratio of 42.91 that indicates a highly leveraged position. Short-term liquidity is constrained by a current ratio of 0.35, which suggests that current liabilities substantially exceed current assets, creating potential pressure on working capital management. Return on Equity is negative at -43.0% and Return on Assets is -13.2%, metrics that collectively reveal that management effectiveness has been diminished by the inability to generate returns on the capital base or asset inventory. The negative profit margin of -78.7% further underscores the operational difficulties in converting sales into earnings under the current financial conditions.
Valuation Assessment
Valuation metrics for China Pharma Holdings, Inc. present mixed signals, as the P/E Ratio (TTM) and Forward P/E are both listed as N/A due to the company's lack of positive earnings. The absence of a traditional P/E multiple implies that standard earnings-based valuation models are inapplicable, forcing reliance on alternative metrics to assess value. The price-to-book ratio is 0.39, indicating that the market values the company at less than one-third of its book value, which often suggests the market perceives significant intangible liabilities or expects substantial future value destruction. Additionally, the price-to-sales ratio stands at 0.79 and the EV/EBITDA is -4.00, suggesting that the market is pricing the stock based on revenue generation rather than profitability, as the negative EV/EBITDA confirms the company is not currently generating economic profit. The stock has traded between a 52-week high of $3.10 and a 52-week low of $0.50, meaning the current price sits somewhere within this range, reflecting high volatility typical of micro-cap stocks. The beta of 1.21 indicates that the stock price is more volatile than the broader market, amplifying both potential gains and losses relative to general market movements. These combined metrics suggest a high-risk valuation profile where investors are compensated for the lack of earnings stability and high leverage.
Growth & Income
Revenue growth year-over-year is -31.3%, while earnings growth is N/A due to the absence of prior period positive earnings, indicating that the business is contracting rather than expanding. Since earnings are negative, they cannot grow faster than revenue in a traditional sense; instead, the contraction in revenue and the widening loss suggest a deteriorating operational trajectory. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all available cash flow, theoretically for reinvestment into growth or debt reduction rather than shareholder distributions. Consequently, the overall growth and income profile is characterized by declining revenue, a lack of current profitability, and no income generation through dividends, positioning the asset as a speculative investment reliant on future operational turnaround rather than current financial performance.